Who is sponsoring NCT05048953?

NCT05048953 is sponsored by B.P. Koirala Institute of Health Sciences.

What drugs are being tested in NCT05048953?

Interventions in NCT05048953: Muscle ultrasound measurements (the index test).

What condition does NCT05048953 study?

NCT05048953 studies ICU Acquired Weakness.

Is NCT05048953 still recruiting?

NCT05048953 is currently completed. Last updated 22 December 2023.

Last reviewed 2023-12-22 · How we verify

NCT05048953

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Use of Musculoskeletal Ultrasound for the Detection of ICU-Acquired Weakness

Completed Last updated 22 December 2023

What this trial tests

trial testing Muscle ultrasound measurements (the index test) in ICU Acquired Weakness in 114 participants. Completed in 1 November 2022.

Timeline

1 October 2021

Primary endpoint
1 November 2022

1 November 2022

Quick facts

Lead sponsor	B.P. Koirala Institute of Health Sciences
Status	Completed
Study type	OBSERVATIONAL
Enrollment	114
Start date	1 October 2021
Primary completion	1 November 2022
Estimated completion	1 November 2022
Sites	1 location across Nepal

Drugs / interventions tested

Muscle ultrasound measurements (the index test)

Conditions studied

ICU Acquired Weakness — all drugs for ICU Acquired Weakness →

Sponsor

B.P. Koirala Institute of Health Sciences

Who can join

16 and older, any sex, with ICU Acquired Weakness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intensive Care Unit-Acquired Weakness (ICU-AW) is a clinical entity frequently encountered in critically ill patients that have both short term and long-term implications. The current gold standard of diagnosis is by assessment of manual muscle strength, using the 6-grade Medical Research Council (MRC) sum score. However, not all Intensive Care Unit (ICU) admitted patients are conscious or cooperative enough to use MRC sum score for the diagnosis of ICU-AW. Ultrasound imaging of muscles has emerged as a valid and reliable tool for providing qualitative and quantitative details about muscle disease and has been suggested as an alternative to assess ICU-AW in critically ill patients in whom the MRC cannot be assessed. This study will be a prospective observational study to evaluate the relationship between the trend of changes in muscle thickness, echogenicity and fasciculations during the first 7 days of ICU stay as measured by ultrasound and ICU-AW among critically ill patients. The study will be performed in the ICU of TU Teaching Hospital, Kathmandu, Nepal for 1 year. All newly admitted adult patients ≥ 16 years of age, expected to stay in ICU / critical care areas for at least 7 days, barring the exclusion criteria, will be included in the study and evaluated for MRC sum score and skeletal muscle thickness, echogenicity and fasciculations using ultrasound on day 1, day 4 and day 7. The measurements will then be statistically analyzed to see if there is any relationship between trend of changes in muscle thickness, echogenicity and fasciculations and ICU-AW

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for ICU Acquired Weakness

Currently open trials in the same condition.

NCT07167121 — Predictive Validity of the Chelsea Critical Care Physical Assessment Tool (CPAx) for Regaining Autonomy Three Months Aft · recruiting
NCT07162948 — ICU-Recover Box 2.0, Smart Technology for Home Monitoring of ICU Patients · NA · recruiting
NCT06592144 — TESTO-TRIAL: Use of Testosterone in Critically Ill Patients · Phase 4 · active not recruiting
NCT05919940 — Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO ) · NA · recruiting
NCT05865314 — Optimised Nutritional Therapy and Early Physiotherapy in Long Term ICU Patients (NutriPhyT Trial) · NA · recruiting

Other B.P. Koirala Institute of Health Sciences trials

Trials by the same sponsor.

NCT07285447 — Re-use of Ambu aScope During Exploration of the Common Bile Duct for Stones in Low-Resource Settings- a Retrospective St · completed
NCT06713733 — Comparison of Clinical Efficacy of Submucosal Dexamethasone and Oral Trypsin-chymotrypsin for Reduction of Postoperative · NA · recruiting
NCT07003581 — Cardiometabolic Risk Factors Associated With Multidrug-Resistant Tuberculosis · completed
NCT06146491 — A COMPARISON OF TRANSDERMAL DICLOFENAC AND ORAL COMBINATION OF PARACETAMOL AND IBUPROFEN IN POSTOPERATIVE PAIN MANAGEMEN · Phase 4 · unknown
NCT07378462 — A Retrospective Randomized Controlled Study Comparing the Effectiveness of Low-level Laser Therapy and Ultrasound Therap · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05048953 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by B.P. Koirala Institute of Health Sciences
Last refreshed: 22 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05048953.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing